Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group | Zendy

Geoffrey J. Gorse | Zendy; Ellen Y. Yang | Zendy; Robert B. Belshe | Zendy; P W Berman | Zendy

Open Access

Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group

Author(s) -

Geoffrey J. Gorse,

Ellen Y. Yang,

Robert B. Belshe,

P W Berman

Publication year - 1996

Publication title -

clinical and diagnostic laboratory immunology

Language(s) - English

Resource type - Journals

eISSN - 1098-6588

pISSN - 1071-412X

DOI - 10.1128/cdli.3.6.769-773.1996

Subject(s) - virology , antibody , saliva , recombinant dna , human immunodeficiency virus (hiv) , immunology , glycoprotein , medicine , virus , lentivirus , biology , viral disease , microbiology and biotechnology , biochemistry , gene

Salivary binding antibodies induced by candidate human immunodeficiency virus type 1 (HIV-1) vaccines in healthy, HIV-1 uninfected volunteers were assessed in a clinical trial evaluating intramuscularly injected HIV-1MN recombinant gp120 (rgp120) vaccine alone or with HIV-1IIIB rgp120 vaccine. The two rgp120 vaccines induced envelope glycoprotein-specific immunoglobulin G (IgG) and IgA antibodies in whole saliva and serum.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research